Company Description
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide.
Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5336 and ABI-1179, which are in Phase 1a/1b clinical studies for recurrent genital herpes; ABI-4334, a capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus that is in Phase 1b clinical study; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study.
The company also develops ABI-7423, an oral broad-spectrum non-nucleoside polymerase inhibitor that targets transplant-related herpesviruses.
It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies.
The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014.
Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2005 |
| IPO Date | Dec 17, 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 73 |
| CEO | Jason Okazaki |
Contact Details
Address: Two Tower Place, 7th Floor South San Francisco, California 94080 United States | |
| Phone | 833 509 4583 |
| Website | assemblybio.com |
Stock Details
| Ticker Symbol | ASMB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001426800 |
| CUSIP Number | 045396108 |
| ISIN Number | US0453962070 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jason A. Okazaki J.D. | Chief Executive Officer, President and Director |
| Dr. William E. Delaney IV, Ph.D. | Chief Scientific Officer |
| Dr. Nicole S. White Ph.D. | Chief Manufacturing Officer |
| Jeanette M. Bjorkquist | Executive Director of Accounting and Treasury |
| Shannon Ryan | Senior Vice President of Investor Relations, Corporate Affairs and Alliance Management |
| Jennifer A. Troia MHROD, SHRM-SCP, SPHR | Chief Human Resources Officer |
| Dr. Anuj Gaggar M.D., Ph.D. | Chief Medical Officer |
| Thomas E. Rollins | Executive Officer |
| Amy Figueroa C.F.A. | Investor Relations Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 23, 2025 | ARS | Filing |
| Apr 1, 2025 | EFFECT | Notice of Effectiveness |
| Mar 20, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 20, 2025 | 10-K | Annual Report |
| Mar 20, 2025 | 8-K | Current Report |
| Feb 20, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Jan 3, 2025 | 8-K | Current Report |